Teva Pharmaceuticals is being fined $503 million (€463 million) by the European Commission for delaying competition posed by rival generic drugmakers, the company's second major financial penalty this month.

BRUSSELS (AP) — The European Commission said Thursday it has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly seeking to protect the patent for its multiple sclerosis drug and for disparaging a rival company ...

Teva Pharmaceutical Industries Ltd. has been fined nearly €463 million ($503 million) by the European Union’s antitrust watchdog for thwarting fair competition by unfairly disparaging a rival maker of a multiple sclerosis drug.